JP2012508215A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508215A5
JP2012508215A5 JP2011535129A JP2011535129A JP2012508215A5 JP 2012508215 A5 JP2012508215 A5 JP 2012508215A5 JP 2011535129 A JP2011535129 A JP 2011535129A JP 2011535129 A JP2011535129 A JP 2011535129A JP 2012508215 A5 JP2012508215 A5 JP 2012508215A5
Authority
JP
Japan
Prior art keywords
salt
salt according
optionally
degrees
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011535129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064889 external-priority patent/WO2010055027A2/en
Publication of JP2012508215A publication Critical patent/JP2012508215A/ja
Publication of JP2012508215A5 publication Critical patent/JP2012508215A5/ja
Withdrawn legal-status Critical Current

Links

JP2011535129A 2008-11-11 2009-11-10 有機化合物 Withdrawn JP2012508215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168862 2008-11-11
EP08168862.4 2008-11-11
PCT/EP2009/064889 WO2010055027A2 (en) 2008-11-11 2009-11-10 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015089480A Division JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Publications (2)

Publication Number Publication Date
JP2012508215A JP2012508215A (ja) 2012-04-05
JP2012508215A5 true JP2012508215A5 (enExample) 2012-12-20

Family

ID=42062355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011535129A Withdrawn JP2012508215A (ja) 2008-11-11 2009-11-10 有機化合物
JP2015089480A Withdrawn JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015089480A Withdrawn JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Country Status (20)

Country Link
US (2) US8680146B2 (enExample)
EP (1) EP2358660A2 (enExample)
JP (2) JP2012508215A (enExample)
KR (1) KR20110086142A (enExample)
CN (2) CN102256933A (enExample)
AU (1) AU2009315735B2 (enExample)
BR (1) BRPI0921533A2 (enExample)
CA (1) CA2741974A1 (enExample)
CL (1) CL2011001041A1 (enExample)
CO (1) CO6382154A2 (enExample)
EC (1) ECSP11011121A (enExample)
IL (1) IL212073A0 (enExample)
MA (1) MA32877B1 (enExample)
MX (1) MX2011004924A (enExample)
NZ (1) NZ591999A (enExample)
PE (1) PE20120012A1 (enExample)
RU (1) RU2543621C2 (enExample)
TN (1) TN2011000187A1 (enExample)
WO (1) WO2010055027A2 (enExample)
ZA (1) ZA201102272B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
JP2012508215A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
EP2456752A2 (en) * 2009-07-24 2012-05-30 ratiopharm GmbH Process for producing fingolimod salts
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
BR112013010075A2 (pt) 2010-10-28 2017-10-24 Mapi Pharma Ltd compostos intermediários e processo para a preparação de fingolimod
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2505589A1 (en) 2011-04-01 2012-10-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
JP6484567B2 (ja) 2013-03-05 2019-03-13 バイオコン・リミテッドBiocon Limited 2−アミノ−1,3−プロパンジオール化合物およびその塩の製造のための方法
US10022340B2 (en) 2013-10-11 2018-07-17 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
CN107530301A (zh) * 2015-01-20 2018-01-02 汉达医药有限责任公司 稳定的固体芬戈莫德剂型
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CN108135907A (zh) 2015-08-21 2018-06-08 奥尔德拉医疗公司 氘化化合物和其用途
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
AU2017275209C1 (en) 2016-05-31 2020-01-23 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
AU2018377036B2 (en) 2017-11-29 2022-04-14 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
BR112020026359A2 (pt) * 2018-06-29 2021-03-30 Forma Therapeutics, Inc. Sais de (s)-(5-ciclobutóxi-2-metil-6-(1-(piperidin-4-il)-1h-pirazol-4-il)-3,4-di-hidroquinolin-1(2h)-il)(ciclopropil)metanona e formas sólidas dos mesmos
EP3833660A4 (en) * 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
TW202131921A (zh) 2019-10-31 2021-09-01 瑞士商愛杜西亞製藥有限公司 Cxcr7拮抗劑與s1p1受體調節劑之組合
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
US20240262783A1 (en) * 2021-05-31 2024-08-08 Shanghai Bocimed Pharmaceutical Co., Ltd. Pharmaceutical salt of fingolimod, preparation method, pharmaceutical composition and use thereof
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ECSP951461A (es) 1995-06-07 1998-04-07 SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B)
ECSP972265A (es) 1997-09-23 1998-11-30 Dihidrato de d-olanzapina
FR2785607B1 (fr) 1998-11-09 2001-02-09 Rhodia Chimie Sa Procede de preparation de tris(ether-amine)
ATE288414T1 (de) * 1998-11-11 2005-02-15 Novartis Pharma Gmbh Herstellung von 2-amino-2(2-(4- alkylphenyl)äthyl)propan-1,3-diolen
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
NZ529044A (en) * 2001-06-08 2008-03-28 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
CA2483594C (en) * 2002-05-16 2011-02-15 Novartis Ag Use of edg receptor binding agents in cancer
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
DE202004021680U1 (de) 2003-04-08 2010-04-22 Novartis Ag Feste pharmazeutische Zusammensetzung
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
RU2008116578A (ru) * 2005-09-30 2009-11-10 Новартис АГ (CH) Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
WO2007143081A2 (en) * 2006-06-02 2007-12-13 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
US7985586B2 (en) * 2008-02-04 2011-07-26 Georgia Health Sciences University Oligodendrocyte precursor cell composition and methods of use
JP2012508215A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物

Similar Documents

Publication Publication Date Title
RU2011123365A (ru) Соли финголимода
RU2011123371A (ru) Кристаллические формы гидрохлорида финголимода
ES2683355T3 (es) Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
JP2018035160A5 (enExample)
JP2011527333A5 (enExample)
HRP20210928T1 (hr) Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola
JP2010514829A5 (enExample)
JP2013525444A5 (enExample)
ME02275B (me) Polimorfni oblik rotigotina
JP2011522816A5 (enExample)
JP2010518061A5 (enExample)
RU2013107748A (ru) Производные с-арилглюкозидов, способ их получения и фармацевтическое применение
JP2012523395A5 (enExample)
JP2009084270A5 (enExample)
JP2017527578A5 (enExample)
JP2021536511A5 (enExample)
JP2011510014A5 (enExample)
JP2010514831A5 (enExample)
RU2011145054A (ru) Кристаллические формы саксаглиптина
JP2015145426A5 (enExample)
JP2010514832A5 (enExample)
JP2024540183A5 (enExample)
JP2020510661A5 (enExample)
JP2010529203A5 (enExample)
JP2014530818A5 (enExample)